J 2021

Levels of endothelial substances in patients with newly identified hypertension compared with healthy controls

BIEL, Vladislav, Jan NOVÁK, Veronika ŘÍMALOVÁ, Marie TOMANDLOVÁ, Josef TOMANDL et. al.

Basic information

Original name

Levels of endothelial substances in patients with newly identified hypertension compared with healthy controls

Authors

BIEL, Vladislav (203 Czech Republic, guarantor, belonging to the institution), Jan NOVÁK (203 Czech Republic, belonging to the institution), Veronika ŘÍMALOVÁ (203 Czech Republic), Marie TOMANDLOVÁ (203 Czech Republic, belonging to the institution), Josef TOMANDL (203 Czech Republic, belonging to the institution), Jiří ŠPÁC (203 Czech Republic, belonging to the institution) and Miroslav SOUČEK (203 Czech Republic, belonging to the institution)

Edition

Biomedical papers, Olomouc, Palacky University, 2021, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.648

RIV identification code

RIV/00216224:14110/21:00121006

Organization unit

Faculty of Medicine

UT WoS

000722224100008

Keywords in English

hypertension; nitric oxide; plasma; endothelial dysfunction

Tags

International impact, Reviewed
Změněno: 27/1/2022 11:06, Mgr. Tereza Miškechová

Abstract

V originále

Endothelial dysfunction occurs at the very beginning of hypertension. The primary goal of our study was to determine plasmatic levels of multiple endothelial substances in otherwise healthy patients with primary hypertension and compare them to healthy individuals. We identified a decrease in total NOx plasmatic levels in otherwise healthy patients with primary hypertension that was more profound in patients with resistant hypertension

Links

MUNI/A/1403/2019, interní kód MU
Name: Diferenciální diagnostika a odhad prognózy interních nemocí 4 (Acronym: DIDIPRON 4)
Investor: Masaryk University, Category A